Date:	--/--/-- --:--:--
Event Id:	E5DAV3ZLN
Action Type:	ACQUISITION
Action Status:	ANNOUNCED
Acquirer Symbol:
Target Symbol:	MEHCQ
Updated:	--/--/-- --:--:--
Purchase Price Per Share:
Price Per Share Currency:
News References:	https://www.globenewswire.com/news-release/2025/05/19/3083895/0/en/Regeneron-Enters-into-Asset-Purchase-Agreement-to-Acquire-23andMe-for-256-Million-Plans-to-Maintain-Consumer-Genetics-Business-and-Advance-Shared-Goals-of-Improving-Human-Health-an.html

Action Notes

Regeneron Pharmaceuticals, Inc today announced it has been named the successful bidder in the bankruptcy auction for substantially all of the assets of 23andMe Holding Co., a leading human genetics and biotechnology company. Regeneron intends to acquire 23andMe's Personal Genome Service(R) (PGS), Total Health and Research Services business lines, together with its Biobank and associated assets, for $256 million and for 23andMe to continue all consumer genome services uninterrupted. Subject to bankruptcy court and regulatory approvals and other customary closing conditions, the transaction is expected to close in the third quarter of 2025.